Loading patent…
OwnerDaniel Cohen, Marta Blumenfeld +2inventors
InventorsDaniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret
Estimating the term…
The present invention relates to PG1, a gene associated with prostate cancer. The invention provides polynucleotides including biallelic markers derived from PG1 and from flanking genomic regions. Primers hybridizing to these biallelic markers and regions flanking are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and prostate cancer and between a haplotype and prostate cancer. The invention also relates to diagnostic methods of determining whether an individual is at risk for developing prostate cancer, and whether an individual suffers from prostate cancer as a result of a mutation in the PG1 gene.
A recombinant, purified or isolated polynucleotide comprising a mammalian PG1 gene, cDNA, complement thereof, or fragment thereof having at least 10 nucleotides in length.
A polynucleotide selected from SEQ ID NOs:
A purified or isolated polypeptide comprising a mammalian PG1 protein, or fragment thereof having at least 8 amino acids in length.
A mammalian host cell comprising a PG1 gene disrupted by homologous recombination with a knock out vector.
A nonhuman host mammal comprising a PG1 gene disrupted by homologous recombination with a knock out vector.
A method of determining whether an individual is at risk of developing cancer or prostate cancer, or whether said individual suffers from cancer or prostate cancer as a result of a mutation in the PG1 gene comprising:
A method of determining whether an individual is at risk of developing cancer or prostate cancer or whether said individual suffers from cancer or prostate cancer as a result of a mutation in the PG1 gene comprising:
A method of obtaining an allele of the PG1 gene which is associated with a detectable phenotype comprising:
A method of obtaining an allele of the PG1 gene which is associated with a detectable phenotype comprising:
A method of categorizing the risk of prostate cancer in an individual comprising the step of assaying a sample taken from the individual to determine whether the individual carries an allelic variant of PG1 associated with an increased risk of prostate cancer.
A method of genotyping comprising determining the identity of a nucleotide at a PG1-related biallelic marker in a biological sample.
A method of estimating the frequency of an allele in a population comprising determining the proportional representation of a nucleotide at a PG1-related biallelic marker in a pooled biological sample derived from said population.
A method of detecting an association between a genotype and a phenotype, comprising the steps of:
A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:
An isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides of SEQ ID No 179 or the complements thereof, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID No 179:
An isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides of SEQ ID No 3 or the complements thereof, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID No 3:
An isolated, purified, or recombinant polynucleotide which encodes a polypeptide comprising a contiguous span of at least 8 amino acids of SEQ ID No 4, wherein said contiguous span includes at least 1 of the amino acid positions 1-26, 295-302, and 333-353
An isolated, purified, or recombinant polypeptide comprising a contiguous span of at least 8 amino acids of SEQ ID No 4, wherein said contiguous span includes at least 1 of the amino acid positions 1-26, 295-302, and 333-353
An isolated or purified antibody composition are capable of selectively binding to an epitope-containing fragment of a polypeptide according to claim 55, wherein said epitope comprises at least 1 of the amino acid positions 1-26, 295-302, and 333-353
A computer readable medium having stored thereon a sequence selected from the group consisting of a nucleic acid code comprising one of the following:
A computer readable medium having stored thereon a sequence consisting of a polypeptide code comprising a contiguous span of at least 8 amino acids of SEQ ID No 4, wherein said contiguous span includes at least 1 of the amino acid positions 1-26, 295-302, and 333-353.
A method for comparing a first sequence to a reference sequence, comprising the steps of:
Dependencies are inferred from the claim text.